FDA Approves Vorasidenib for Adults, Pediatric Patients With Grade 2 Astrocytoma, Oligodendroglioma
August 7th 2024This marks the first FDA-approved systemic therapy for patients with grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IHD1) or IDH2 mutation.
Read More
Intravenous Immunoglobulin Preparations Leads to Varied Effects in Patients With Kawasaki Disease
August 6th 2024Two different brands of intravenous immunoglobulin have been investigated, finding Brand P led to significantly longer durations of fever and hospitalization when compared to brand T.
Read More